The continuum of care for ALK positive NSCLC: from diagnosis to new treatment options an overview.
The role of the ALK receptor in cancer biology B. Hallberg R. H. Palmer iii4 Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? K. M. Kerr F. Lopez Rios iii16 ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM) the Cologne model for implementing personalised oncology C. Heydt, A. Kostenko, S. Merkelbach Bruse, J. Wolf R. Buttner iii25 Crizotinib: from discovery to accelerated development to front line treatment F. Blackhall F. Cappuzzo iii35 Crizotinib resistance: implications for therapeutic strategies I. Dagogo Jack A. T. Shaw iii42
Annals of oncology official journal of the European Society for Medical Oncology